Guidance for PTC Therapeutics (PTCT)
| Period | Range | Estimate | Revenue Range | Revenue Estimate | Target | Details |
|---|---|---|---|---|---|---|
| 2026 | N/A | N/A | $700.00M – 800.00M | $990.30M |  Lowered |
Details |
| 2025 | N/A | N/A | $750.00M – 800.00M | N/A | = Maintained | Details |
| 2025 | N/A | N/A | $650.00M – 800.00M | $1746.00M | = Maintained | Details |
| 2025 | N/A | N/A | $650.00M – 800.00M | $829.90M | = Maintained | Details |
| 2024 | N/A | N/A | $750.00M – 800.00M | $734.00M | = Maintained | Details |
| 2024 | N/A | N/A | $600.00M – 680.00M | $606.60M | = Maintained | Details |
| Q1 2024 | N/A | N/A | $600.00M – 680.00M | N/A | = Maintained | Details |
| 2023 | N/A | N/A | $0.94B – 1.00B | N/A | = Maintained | Details |
| 2023 | N/A | N/A | $0.94B – 1.00B | $0.90B | = Maintained | Details |
| Q3 2022 | N/A | N/A | $700.00M – 750.00M | $722.95M | = Maintained | Details |
| 2019 | N/A | N/A | $285.00M – 305.00M | $314.80M | = Maintained | Details |
| 2018 | N/A | N/A | $260.00M – 280.00M | $276.02M | = Maintained | Details |
| 2018 | N/A | N/A | $260.00M – 295.00M | $249.15M | = Maintained | Details |
| Q2 2018 | N/A | N/A | $260.00M – 295.00M | N/A | = Maintained | Details |
| Q4 2017 | N/A | N/A | N/A | N/A | = Maintained | Details |
| Q3 2017 | N/A | N/A | N/A | N/A | = Maintained | Details |
| Q2 2017 | N/A | N/A | N/A | N/A | = Maintained | Details |
| Q1 2017 | N/A | N/A | N/A | N/A | = Maintained | Details |
